Review Article

Safety & effectiveness of COVID-19 vaccines: A narrative review

Francesco Chirico¹, Jaime A. Teixeira da Silva², Panagiotis Tsigaris³ & Khan Sharun⁴

¹Department of Public Health, Post-graduate School of Occupational Medicine, Catholic University of the Sacred Heart, Rome, Italy, ²Independent Researcher, Kagawa-Ken, Japan, ³Department of Economics, Thompson Rivers University, Kamloops, British Columbia, Canada & ⁴Division of Surgery, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India

Received February 14, 2021

There are currently eight vaccines against SARS-CoV-2 that have received Emergency Use Authorization by the WHO that can offer some protection to the world’s population during the COVID-19 pandemic. Though research is being published all over the world, public health officials, policymakers and governments are collecting evidence-based information to establish the public health policies. Unfortunately, continued international travel, violations of lockdowns and social distancing, the lack of mask use, the emergence of mutant strains of the virus and lower adherence by a sector of the global population that remains sceptical of the protection offered by vaccines, or about any risks associated with vaccines, hamper these efforts. Here we examine the literature on the efficacy, effectiveness and safety of COVID-19 vaccines, with an emphasis on select categories of individuals and against new SARS-CoV-2 strains. The literature shows that these eight vaccines are highly effective in protecting the population from severe disease and death, but there are some issues concerning safety and adverse effects. Further, booster shots and variant-specific vaccines would also be required.

Key words Adverse effect - clinical trials - COVID-19 - efficacy - neutralization potential - risks - safety - SARS-CoV-2

The World Health Organization (WHO) list of Emergency Use Authorization (EUA)-qualified COVID-19 vaccines (as on 20 December, 2021) contains eight vaccines, namely the three adenoviral-vectored vaccines ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca), Ad26.CoV2.S (Janssen), Covishield, CrAdOx1, nCoV-19 (Serum Institute of India), two whole-inactivated coronavirus, which are the Covilo/BBIBP-CorV (SinoPharm/Beijing Institute of Biological Products), CoronaVac (Sinovac) and Covaxin, BBV152 (Bharat Biotech), and the messenger RNA (mRNA) vaccines mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech). mRNA vaccines work by injecting mRNA that encodes the SARS-CoV-2 spike protein directly into the host and have several advantages over conventional vaccine types, including improved safety, low potential for mutations, lower risk of antigen degradation in vivo and the potential for rapid mass production at a lower cost, although there are still challenges remaining regarding their pharmacological stability.

Another mRNA vaccine, CureVac, was developed in the European Union (EU) by CureVac N.V. and the
Coalition for Epidemic Preparedness Innovations, with the hope of being cheaper and lasting longer than other mRNA vaccines, but results on June 16, 2021 from a 40,000-person phase III two-dose trial found it 47 per cent effective at preventing the disease, which was lower than the ≥50 per cent requirement for approval by the WHO. Other vaccines produced by Janssen, AstraZeneca, Sputnik-V and CanSino, use human and primate adenovirus vectors. The vaccines manufactured by Novavax and GSK/Sanofi companies consist of purified pre-fusion stabilized SARS-CoV-2 spike protein, which is given in combination with an adjuvant to boost the immune response. On June 1, 2021, the WHO validated the use of the Chinese Sinovac - CoronaVac COVID-19 vaccine for emergency use, although with interim policy recommendations. CoronaVac is an inactivated vaccine with easy storage requirements. It was only 51 per cent effective at preventing COVID-19 in late-stage trials. The vaccine’s safety, immunogenicity and efficacy need to be tested across the three phases of clinical trials, although protection against severe disease and death is difficult to assess only in phase 3 clinical trials.

Vaccination against COVID-19 started in India on January 16, 2021. The Indian government and States launched an extensive vaccination campaign against COVID-19, targeting 300 million beneficiaries of priority groups such as healthcare and frontline workers and individuals older than 50. India’s drug regulator (Central Drugs and Standards Committee - CDSCO) approved restricted emergency use of Covishield and Covaxin in India. Covishield (AstraZeneca vaccine ChAdOx1/AZD1222), approved for EUA by the WHO, is a two-dose version of the Oxford/AstraZeneca vaccine manufactured by the Serum Institute of India, while Covaxin (BBV152 vaccine) is an inactivated-virus vaccine. Phase I (safety and immunogenicity) and phase II trial (immune response and safety) data of Covaxin are published. A phase 3 study confirmed the clinical efficacy of BBV152 against symptomatic COVID-19 disease and safety monitoring and assessment did not raise concerns about the vaccine.

In April 2021, the Indian Government approved Sputnik V as a third vaccine. Sputnik V (Gam-COVID-Vac), which is a dual vector-based vaccine that combines type 26 and rAd5 recombinant adenovirus (rAd), exhibited 91.6 per cent efficacy against COVID-19. Sinopharm’s BBIBP-CorV (Covilo) showed 79 per cent efficacy against symptomatic SARS-CoV-2 infection and hospitalization in a large multi-country phase III trial after administering two doses 21 days apart, but efficacy could not be determined in people aged 60+ and with comorbidities, and there was an underrepresentation of women.

In October 2021, India crossed the one billion vaccine doses milestone and by January 16, 2022, 70 per cent adult population was fully vaccinated.

### Efficacy/effectiveness of current COVID-19 vaccines

A systematic review on the efficacy of vaccines covering studies from January 1 to May 14, 2021 identified 30 studies, showed 80-90 per cent vaccine efficacy against symptomatic and asymptomatic infections in fully vaccinated people in nearly all studies. In clinical trials, three vaccines had higher (>90%) efficacy against COVID-19 infection [Pfizer-BioNTech (~95%), Moderna (~94%) and Sputnik V (~92%)] than the vaccines by Oxford-AstraZeneca (~70%) and Janssen (54-72%), against moderate and severe forms of COVID-19 infection. The mRNA vaccines showed high efficacy against infection and a very high level of protection against severe disease, hospitalization and death while the risk of severe forms of COVID-19 infection and deaths was reduced by Moderna, Sputnik V, Janssen and Oxford-AstraZeneca vaccines. In contrast, this information was not available in the published trials for the Pfizer-BioNTech vaccine. Compared to the Pfizer vaccine, the Moderna vaccine can be kept at higher temperatures, making it easier to transport and store. Other vaccines produced by other companies, and with positive efficacy results, received EUA status in some countries. The longitudinal assessment of vaccine participants is a necessary critical assessment because it provides information on whether vaccination can achieve long-lasting immunity.

Although most evidence suggests that ‘immune responses elicited by SARS-CoV-2 infection are present and might protect against’ reinfection, but the experience with seasonal coronaviruses and the present experience with SARS-CoV-2 suggest that immunity to natural infection might wane over time, as reinfection cases occur. For this reason, an extra booster dose can continue to offer protection.

Regarding the interchangeability of COVID-19 vaccines, the WHO recommends using the same COVID-19 vaccine for both doses of a two-dose schedule, but there is scientific evidence of the
effectiveness of heterologous vaccination with AstraZeneca or Covishield as the first dose and an mRNA vaccine as the second dose\textsuperscript{28-30}.

### Safety and adverse effects of current COVID-19 vaccines

As shown in Table I, current vaccines have demonstrated considerable efficacy in diminishing mild, moderate and severe cases with a low risk of adverse events\textsuperscript{21}. For some of these vaccines [such as Convidicéa (AD5-nCoV), Janssen (Ad26.COV2.S), Sinopharm (BBIBP-CorV), Covaxin (BBV152) and Sinovac (CoronaVac)], there is the information available on their immunogenicity and safety from phase I and II vaccine recipients, but evidence of their effectiveness is not clear\textsuperscript{31}. Due to urgency, health regulatory agencies such as the EMA in the EU and the Food and Drug Administration (FDA) in the US evaluated only short-term adverse effects before their authorization. Records of adverse events in trial results on the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech vaccine) continued up to six months from the second dose\textsuperscript{39}. Mild-to-moderate local responses such as discomfort, redness or inflammation at the injection site were the most commonly reported adverse effects in the clinical trials, while systemic events included fatigue, headache, body aches and fever\textsuperscript{39}. There were four serious issues among BNT162b2 participants in a clinical trial: shoulder injury from vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia and right leg paresthesia\textsuperscript{39}. Another adverse reaction in the Pfizer-BioNTech trial was lymphadenopathy with 64 vaccine recipients (0.3%) versus only six in the placebo group (<0.1%)\textsuperscript{39}. The clinical trial on the mRNA-1273 COVID-19 vaccine, manufactured by ModernaTX Inc., reported no serious adverse events, while moderate or mild adverse events included headache, fatigue, myalgia, chills and injection-site discomfort, but these were dose-dependent and more common after the second immunization\textsuperscript{40}.

Myocarditis and pericarditis were reported in individuals receiving mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna SpikeVax), especially in young males after the second dose, so the US Centres for Disease Control and Prevention (CDC) and FDA developed educational material for vaccine recipients and providers that described the possibility of myocarditis and its symptoms to be able to recognize and manage it\textsuperscript{41}. There are insufficient data to describe the efficacy, safety and effectiveness of the BNT162b2 in children under 16 and the SpikeVax vaccine in individuals under 18\textsuperscript{42}. Although the balance of benefits and risks varied by age and gender, but the benefits of preventing the COVID-19 disease and associated hospitalizations, intensive care unit admissions and deaths outweighed the risks such as expected myocarditis cases after vaccination in all populations for which vaccination was recommended\textsuperscript{41}. There are currently no alternatives to mRNA COVID-19 vaccines for youths, so on May 10, 2021, the FDA expanded the EUA of the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 through 15 yr of age\textsuperscript{41}.

Anaphylaxis has been the only life-threatening condition reported during the vaccination campaign with the Pfizer-BioNTech vaccine, so it has to be appropriately managed and prevented\textsuperscript{43}. Hypersensitivity-related adverse events for Pfizer-BioNTech and Moderna trial participants relative to the placebo groups were 0.12 and 0.4 per cent higher, respectively\textsuperscript{39,40}. In addition, the Pfizer-BioNTech trial reported one ‘drug hypersensitivity reaction’ and one case of anaphylaxis, while Moderna reported two cases of ‘delayed hypersensitivity reactions’\textsuperscript{44}.

By December 23, 2020, among the 1,893,360 first doses of Pfizer-BioNTech vaccines administered in the US, only 0.2 per cent of adverse events were reported and submitted to the Vaccine Adverse Event Reporting System (VAERS)\textsuperscript{45}. As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to VAERS\textsuperscript{46}.

Allergic reactions from the two available mRNA COVID-19 vaccines were due to polyethylene glycol (PEG)\textsuperscript{47}, also known as macrogol, while for the AstraZeneca and Johnson and Johnson COVID-19 vaccines, the filler polysorbate 80, also known as Tween 80, has been implicated in allergic reactions\textsuperscript{48-50}. Allergic reactions are rare, but the CDC recommends avoiding mRNA vaccines in individuals who had anaphylaxis in the past\textsuperscript{42,51}. In addition, the CDC guidance indicates precaution for allergy due to ‘a potential cross-reactive hypersensitivity between ingredients in mRNA and adenovirus vector COVID-19 vaccines’\textsuperscript{52}.

The occurrence of thrombosis with thrombocytopenia syndrome was linked to adenovirus vector vaccines such as ChAdOx1 nCoV-19 (Oxford-
### Table I. Type, regime, efficacy, safety, protection against variants and storage of COVID-19 vaccines listed by the World Health Organization: Findings from clinical trials and preliminary studies

| COVID-19 vaccine                      | Country; date of WHO's listing | Type of vaccine and regimen | Efficacy and safety profile against original virus and variants of concern | Storage | Cost per dose (US$) |
|---------------------------------------|---------------------------------|-----------------------------|-----------------------------------------------------------------------------|---------|---------------------|
| Pfizer BioNTech SE (BNT162b2)         | USA, January 31, 2020           | m-RNA vaccine 2 doses regimen Three weeks apart Use for >12 yr old (for 12-15 yr children with comorbidities this vaccine is suggested) | 92-100% against infection 87% against hospitalization 92% against severe disease A possible causal relationship with very rare cases of myocarditis in young men (16-24) is reported and currently under investigation 75% reduction in neutralization activity against the Beta (B.1.351), 88% reduction against Gamma (P1) and Delta (B.1.617.2) variants, and 93% reduction against Alpha (B.1.1.7) | −70°C for shipping and six months storage 2-8°C for 30 days | 20       |
| Spikevax (Moderna, mRNA-1273)        | USA; April 30, 2021             | m-RNA-vaccine 2 doses regimen Four weeks apart Use for >18 yr old | 94% against infection 100% against severe disease, hospitalization and death (e.g., anaphylaxis) A possible causal relationship with very rare cases of myocarditis in young men is reported and currently under investigation Preliminary results indicate some reduction in neutralization activity against the Beta (B.1.351) variant, and less marked decrease against Gamma (P1), Alpha (B.1.1.7), and Epsilon (B.1.429). The impact of Delta (B.1617.2) is yet to be determined | −20°C for shipping and six months storage 2-8°C for 30 days | 37       |
| Janssen (Johnson and Johnson) (Ad26.CoV2) | March 12, 2021                   | Viral vector Single dose regimen Use for >18 yr old | 66% against infection 77% (after 14 days) to 86% (after 28 days) against severe disease 93% (after 14 days) to 100% (after 28 days) against hospitalization Efficacy was maintained against P2 and B.1.351 variants Very rare severe allergic reactions reported in clinical trials Thrombosis with thrombocytopenia syndrome reported 3-15 days following vaccination | 2-8°C for three months −20°C for two years | 10       |
| Vaxzevrria (Oxford/AstraZeneca) (ChAdOx1) | UK, February 15, 2021          | Viral vector Two doses regimen Four weeks apart for two standard doses 12 wk apart for ½ dose and full dose use for >18 yr old | 92% protection against hospitalization with delta variant; 86% protection against hospitalization with Alfa variant No severe allergic reactions reported in clinical trials Thrombosis with thrombocytopenia syndrome reported 3-30 days following vaccination | 2-8°C (pharmacy) for six months | 4        |
| CoronaVac (Sinovac Biotech Ltd)      | China, June 1, 2021             | Whole cell inactivated vaccine Two doses regimen Two four weeks apart Use for >18 yr old | 50-84% against infection 80-100% in preventing severe COVID-19 infections, hospitalization and deaths 51-83.5% in preventing symptomatic COVID-19 infection Safe and well tolerated in older adults 49.6% against infection (P.1 variant) 50.7% (P. 2 variant) | 2-8°C pharmacy refrigerator | 30       |

Contd...
| COVID-19 vaccine                  | Country; date of WHO’s listing | Type of vaccine and regimen | Efficacy and safety profile against original virus and variants of concern                                                                 | Storage | Cost per dose (US$) |
|----------------------------------|--------------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------------------|
| Covishield™ (Serum Institute of India Pvt. Ltd) (ChAdOx1-S) | India, February 15, 2021 | Viral vector Two doses regimen Four weeks apart for two standard doses 12 wk apart for ½ dose and full dose use for >18 yr old | 72-85% against infection 92% protection against hospitalization with delta variant; 86% protection against hospitalization with Alfa variant No severe allergic reactions reported in clinical trials Thrombosis with thrombocytopenia syndrome reported 3-30 days following vaccination | 2-8°C (pharmacy) for six months |                   |
| BIBP/Sinopharma (Beijing BioInstitute of Biological Products Co. Ltd) | China, May 7, 2021 | Whole cell inactivated vaccine Two doses regime Three-four weeks apart Use for >18 yr old | 79% against infection and hospitalization No severe allergic reactions reported in clinical trials | 2-8°C (pharmacy) |                   |
| Covaxin (Bharat Biotech BBV152) | India, November 3, 2021 | Whole virion inactivated vaccine Two doses regimen Four weeks apart Use for >18 yr | 78% efficacy against infection, hospitalization and deaths | 2-8°C (pharmacy) | 15-20             |

Information gathered above from various sources can be also validated from: https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/on-pins-and-needles-will-COVID-19-vaccines-save-the-world and https://www.statista.com/chart/23510/estimated-effectiveness-of-COVID-19-vaccine-candidates. Cost per dose obtained from: https://www.statista.com/chart/23658/reported-cost-per-dose-of-COVID-19-vaccines and https://observer.com/2020/08/COVID19-vaccine-price-comparison-moderna-pfizer-novavax-johnson-astrazeneca. All vaccines report mild-to-moderate local reactions (e.g., pain, redness, or swelling at the injection) and a few systemic events (e.g., fatigue, headache, body aches, and fever). For information on protection against variants see: https://www.businessinsider.in/science/news/one-chart-shows-how-well-covid-19-vaccines-work-against-the-3-most-worrisome-coronavirus-variants/articleshow/81472174.cms, WHO. Background document on the Bharat Biotech BBV152 Covaxin vaccine against COVID-19. Released on November 3, 2021. Available from: https://extranet.who.int/iris/restricted/bitstream/handle/10665/347044/WHO-2019-nCoV-vaccines-SAGE-recommendation-BBV152-background-2021.1-eng.pdf?sequence=1&isAllowed=y; For the cost of Covaxin: https://www.dnaindia.com/india/report-bharat-biotech-announces-price-of-Covaxin-rs-600-for-states-rs-1200-for-private-hospitals-2887737.
AstraZeneca) and AD26.CoV2·S (Johnson and Johnson), raising concerns\(^43\). For example, a population-based cohort study in Denmark and Norway showed ‘increased rates of venous thromboembolic events, including cerebral venous thrombosis’ in recipients of ChAdOx1, more venous thromboembolic events were observed in the vaccinated cohort than expected in the general population, and the standardized morbidity ratio was significantly greater than unity\(^53\).

ChAdOx1 nCoV-19 vaccine induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis with fatal intracerebral haemorrhaging\(^53\)–\(^55\). Following administration of the Johnson & Johnson vaccine, a case of thrombocytopenia, elevated D-dimers and pulmonary emboli was found\(^65\). EMA reported other blood clots associated with thrombocytopenia, including arterial thromboses and splanchic vein thrombosis, after administration of the AstraZeneca vaccine\(^57\). All patients in each series had high levels of antibodies against antigenic complexes of platelet factor 4, as seen in heparin-induced thrombocytopenia. Therefore, this condition was defined as ‘vaccine-induced immune thrombotic thrombocytopenia’, requiring high-dose immunoglobulins and certain non-heparin anticoagulants for treatment\(^57\)–\(^58\). A case report of Guillain–Barre syndrome followed the administration of the first dose of the ChAdOx1 vaccine\(^59\), and two cases of autoimmune hepatitis were triggered by Covishield vaccination\(^60\).

The Coalition of Epidemic Preparedness Innovations (CEPI) questioned the use of alum and other adjuvants that might promote Th2 responses\(^61\). Moreover, T-helper17 (Th17) inflammatory responses, which play a role in the pathogenesis of COVID-19-related pneumonia and oedema by promoting eosinophilic activation and infiltration, could also explain coronavirus-vaccine immune enhancement\(^62\). Therefore, an understanding of Th17 responses is critical for the successful clinical development and production of COVID-19 vaccines and plays a potential role in selecting vaccine dose, adjuvants and route\(^62\).

Do COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infection? ADE is a complex phenomenon that includes vaccine hypersensitivity (VAH), delayed-type hypersensitivity and/or an Arthus reaction\(^63\). VAH has a complex and poorly defined immunopathology post-vaccination outcome that may be associated with non-protective antibodies\(^64\). ADE in SARS-CoV and MERS-CoV infection showed the development of poorly or non-neutralizing antibodies after vaccination or infection enhance subsequent infections\(^65\). Several SARS-CoV and MERS-CoV vaccines have elicited a post-challenge VAH in laboratory animals. For example, in the 1960s, the formalin-inactivated measles vaccine in children caused VAH 8-12 months after the vaccination, leading to lung lesions, revealing damage to parenchymal tissue, pulmonary neutrophilia with abundant macrophages and lymphocytes and excess eosinophils\(^66\). Lessons learned from adverse effects caused by SARS-CoV and MERS-CoV vaccines may help to develop better immunotherapeutics and vaccines against SARS-CoV-2\(^65\).

Overvaccination in patients predisposed to autoimmune disease may enhance the possibility of developing an autoimmune response\(^65\). Since the mRNA vaccines against COVID-19 are the first mRNA vaccines authorized for the market, there is a possibility that these may generate strong type 1 interferon responses that could lead to inflammation and autoimmune conditions\(^67\).

A vaccine in the market requires safety monitoring surveillance to detect and evaluate rare adverse events not identified in prelicensure clinical trials. In the US, the CDC has three long-standing vaccine safety programmes: VAERS, the Vaccine Safety Datalink and the Clinical Immunization Safety Assessment\(^68\).

Efficacy of the vaccines against new viral strains

Considering that the SARS-CoV-2 virus, like other viruses, mutates\(^69\)–\(^70\), why are some RNA vaccines effective against the new strains of the SARS-CoV-2 virus, while others are less, or not at all? These new variants result from mutations in the viral genomes, occurring due to the consequences of viral replication, which are advantageous to the survival of the virus. Among these variants, WHO, US CDC, and the EU’s European Centre for Disease Prevention identified some variants as being significant variants, referring to them as variants of concern (VOCs) and variants of interest (VOIs) (Table II). VOCs emerged as a more significant threat to public health due to their enhanced transmissibility and infectivity\(^71\). Global concern is the continued spread of the highly transmissible Delta variant, which has become predominant worldwide\(^62\)–\(^73\) and has better transmission potential (60%) than the alpha variant\(^74\). Currently, omicron variant is becoming the predominant strain resulting from a combination
| Variant                  | Next strain | Lineages            | First detected | Country | Date designated | Spread number of nations | Attributes                                                                 |
|--------------------------|-------------|---------------------|----------------|---------|----------------|--------------------------|-----------------------------------------------------------------------------|
| **Variants of concern**  |             |                     |                |         |                |                          |                                                                             |
| Alpha                    | 20I/501Y. V1| B.1.1.7             | September 2020 | UK      | December 18, 2020 | 173                      | Evidence of increased transmissibility (~50% increase) and disease severity based on case fatality and hospitalizations rates |
| Beta                     | 20H/501. V2 | B.1.351 B.1.351.2 B.1.351.3 | May 2020 | South Africa | December 18, 2020 | 122                      | Evidence of increased transmissibility (~50% increase) and has an impact on therapeutics (bamlanivimab and etesevimab) and vaccines (reduced neutralization by post-vaccination serum) |
| Gamma                    | 20J/501Y. V3| P. 1 P. 1.1 P. 1.2 | November 2020 | Brazil | January 11, 2021 | 74                       | Evidence of impact on monoclonal antibody treatments (bamlanivimab and etesevimab) and vaccines (reduced neutralization by post-vaccination serum) |
| Delta                    | 21A/S: 478K | B.1.617.2 AY.1 AY.2 AY.3 | October 2020 | India | May 11, 2021 (VOI: 4 April 2021) | 100                      | Evidence of increased transmissibility and has an impact on monoclonal antibody treatments and vaccines (reduced neutralization by post-vaccination serum) |
| Omicron                  | 21K         | B.1.1.529           | November 2021 | Multiple countries | November 26, 2021 | Not reported yet | Not fully investigated yet |
| **Variants of interest** |             |                     |                |         |                |                          |                                                                             |
| Lambda                   | N/A         | C.37                | December 2020 | Peru    | June 14, 2021   | N/A                      | N/A                                                                         |
| Mu                       | B.1.621     | January 2021        | Columbia       |         |                |                          |                                                                             |

Last updated: 20 December 2021. Information obtained from WHO (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/) there are a number of variants that are being monitored currently and can be found at the WHO as we as at the USA Center of Disease Control and Prevention found (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html); CDC has no VOI listed and only two VOCs: Delta and Omicron; There is also information in the magazine about: https://www.businessinsider.com/COVID-19-vaccine-efficacy-variants-india-south-africa-brazil-uk-2021-5; for transmission see: https://www.aljazeera.com/news/2021/7/7/map-tracking-the-COVID-19-delta-variant. WHO, World Health Organization; CDC, Centres for Disease Control; VOI, variants of interest; VOCs, variants of concerns; N/A, not available
of increased transmissibility and the ability to evade natural and artificial immunization\textsuperscript{75}. WHO monitors the global spread and epidemiology of VOCs and VOIs and coordinates laboratory investigations\textsuperscript{76}.

Several SARS-CoV-2 VOCs have emerged and were originally identified in the UK (variant B.1.1.7 or alpha), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), India (B.1.617.2 or delta) and South Africa (B.1.1.529 or omicron)\textsuperscript{77}. These VOCs are considered severe public health threats because of their association with higher transmissibility, morbidity, mortality and potential immune escape\textsuperscript{78} by infection or vaccine-induced antibodies resulting from the accumulation of mutations in the spike protein\textsuperscript{79}. In other words, these may alter the clinical manifestation of the disease and efficacy of available vaccines and therapeutics, as well as the ability of reverse transcription-polymerase chain reaction (RT-PCR) assays to detect the virus\textsuperscript{80}.

Though the efficacy of the ChAdOx1 nCoV-19 vaccine against the alpha variant was similar to that reported in previous studies\textsuperscript{81}, the vaccine conferred only minimal protection against COVID-19 infection caused by the Beta variant\textsuperscript{82}. The NVX-CoV2373 vaccine (Novavax) also demonstrated efficacy against the Alpha and Beta variants of SARS-CoV-2\textsuperscript{83}. The Novavax vaccine is 86 per cent efficacious against the Alpha variant and 60 per cent efficacious against the Beta variant\textsuperscript{84}. Although the neutralization capacity of several COVID-19 vaccines (mRNA-1273, NVX-CoV2373, BNT162b2 and ChAdOx1 nCoV-19) was reduced against the Beta (B.1.351) variant\textsuperscript{85}, but Covaxin conferred significant protection against both Beta (B.1.351) and Delta (B.1.617.2) variants\textsuperscript{80}.

Similarly, the single-dose Janssen COVID-19 vaccine candidate demonstrated efficacy against the Beta variant\textsuperscript{86}. The Moderna vaccine candidate (mRNA-1273) also demonstrated efficacy against the Alpha and Beta SARS-CoV-2 variants, findings that were based on in vitro neutralization studies conducted using serum collected from individuals vaccinated with the mRNA-1273 vaccine\textsuperscript{87}. Therefore, South Africa adjourned campaigns to vaccinate its front-line health care workers (HCWs) with the Oxford-AstraZeneca vaccine after a small clinical trial suggested that it ineffectively prevented mild to moderate illness from the dominant variant in the country\textsuperscript{88}. The results of a clinical trial confirmed that a two-dose regimen of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine did not protect individuals against the mild-to-moderate B.1.351 variant\textsuperscript{89}.

Mutations observed in the SARS-CoV-2 variants identified in the UK and South Africa had small effects on the effectiveness of the Pfizer-BioNTech vaccine\textsuperscript{90}. A two-strain mathematical framework using Ontario (Canada) as a case study found that, given the levels of under-reporting and case levels at that time, ‘a variant strain was unlikely to dominate’ until the first quarter of 2021, and high vaccine efficacy was required across strains to make it possible to have an immune population in Ontario by the end of 2021\textsuperscript{91}. The UK research showed that the Pfizer–BioNTech vaccine was 92 per cent effective against symptomatic cases of the alpha variant and offered 83 per cent protection against the Delta variant\textsuperscript{82}. A study in Qatar found similar results: the Pfizer–BioNTech vaccine offered 90 per cent protection against the Alpha variant and 75 per cent protection against the Beta variant\textsuperscript{83}. In a US-based study carried out during July 2021, 346 of the 469 COVID-19 cases (74\%) among Massachusetts residents occurred in fully vaccinated people with two doses of Pfizer-BioNTech, Moderna, or a single dose of Janssen vaccine ≥14 days before exposure\textsuperscript{84}. Genomic sequencing of testing identified the new Delta variant in 90 per cent of cases\textsuperscript{86}. Even vaccinated people may get infected with COVID-19 due to the Delta variant, and on July 27, 2021, the US CDC released a recommendation to invite citizens to wear masks in indoor public environments where the risk of COVID-19 transmission is high\textsuperscript{84}.

The neutralization potential of BBV152/Covaxin, the inactivated SARS-CoV-2 vaccine rolled out in India, was also effective against Beta and Delta variants, but since reduced neutralization activity may result in reduced vaccine effectiveness, further studies are needed for Covaxin against these two variants\textsuperscript{78}. A single dose of Pfizer or AstraZeneca offered little protection against the Beta and Delta variants and a neutralizing response was generated against the Delta variant only after the administration of the second dose\textsuperscript{74}. Despite being lower, the remaining neutralization capacity conferred by the Pfizer vaccine against Delta and other VOCs was protective\textsuperscript{85}.

Until February 6, 2022, the WHO described eight variants of interest (VOIs), namely Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621)\textsuperscript{90}. However, there is still a lack of significant clinical data on the vaccine efficacy against these variants. Genomic sequencing and monitoring of the spread of these variants are crucial to understand the impact on vaccine effectiveness and to adjust vaccination strategies accordingly.
of detailed knowledge about their transmissibility, infectivity, re-infectivity, immune escape and vaccine activity\(^6\). A preprint highlighted that the lambda variant (lineage C.37), which spread from Peru in December 2020, displayed increased infectivity and immune escape against the Coronavac vaccine\(^8\). Table II summarizes the profiles of the VOCs and VOIs. The most recent data on the variants reported in India are available at the Indian SARS-CoV-2 Genomic Consortia (INSACOG) website. The predominant SARS-CoV-2 variant currently circulating in India is Delta (B.1.617.2 and AY.4)\(^8\). Covaxin (BBV152) exhibited good protection (65.2\%) against the Delta variant, and although a minor reduction in the neutralizing antibody titre was observed, the sera of vaccinated individuals still effectively neutralized the Delta, Delta AY.1 and B.1.617.3 variants\(^8\). In contrast, breakthrough infections were reported due to the Delta variant in individuals fully vaccinated with Covishield\(^10\).

**Safety and efficacy of the vaccines in select categories of people**

Another issue is that clinical trials are studies conducted on select categories of individuals, generally healthy people. Thus, concerns exist about safety and effectiveness in specific categories of people. For instance, there are doubts that all COVID-19 vaccines can stimulate an immune response in older individuals (≥65 yr), especially those with co-morbidities, such as hypertension, obesity and diabetes mellitus\(^10\). Older patients, especially those older than 65 and with co-morbidities, are more susceptible to a severe form of COVID-19 that can progress rapidly, often leading to death\(^10\). In general, the efficacy of vaccines in older people is not well studied. The impact of immunosenescence on vaccine safety is even more uncertain\(^2\). The presence of chronic diseases (e.g., diabetes) and fragility, including immunodepression, may be better forecasters of weak immunologic responses than age\(^10\).

Even though the safety and efficacy of COVID-19 vaccines in older people are critical to their health\(^2\), no studies have been done to examine the response of this category of individuals to all COVID-19 vaccines. Vaccines developed by the University of Oxford/AstraZeneca (ChAdOx1) and Janssen (Ad26.COV2) depend on the genetic alteration of adenoviruses that are inactivated, due to the replacement of the E1 gene with the spike gene\(^2\). The ChAdOx1 nCoV-19 (AZD1222) vaccine is better tolerated by older than younger people, and after the second dose, it has similar immunogenicity across all ages\(^10\). However, additional assessment of AZD1222 is planned\(^10\). A second trial on the Moderna vaccine showed binding- and neutralizing-antibody responses in older people (>55 yr), similar to previously reported vaccine recipients between 18 and 55 yr of age\(^4\).

Pregnant and lactating women are excluded from vaccine research because they are not recognized as a high-priority group, despite the risk of complications and poor perinatal outcomes\(^10\), and because of previous experience of pregnancies complicated by infection with other coronaviruses, such as SARS-CoV and MERS-CoV, making pregnant women vulnerable to severe SARS-CoV-2 disease\(^7\). A retrospective study based on clinical criteria confirmed that pregnancy significantly increased the risk of severe COVID-19\(^10\). Based on a review of maternal and neonatal COVID-19 morbidity and mortality data, the COVID-19 vaccines should be administered to those at the highest risk of severe infection until the safety and efficacy of vaccines are thoroughly validated\(^10\). Therefore, in consultation with their obstetricians, pregnant women will need to consider the benefits and risks of COVID-19 vaccines. The US CDC, the American College of Obstetricians and Gynaecologists and the Society for Maternal-Foetal Medicine each issued guidance supporting vaccination in pregnant individuals\(^10\).

Another critical issue concerns COVID-19 vaccination in children. Children of any age are susceptible to SARS-CoV-2 infection, including severe disease manifestations. Previously healthy children are also at risk of severe COVID-19 and multisystem inflammatory syndrome in children (MIS-C)\(^8\). Children might differ from adults in terms of the safety, reactogenicity and immunogenicity of vaccines\(^8\). Paediatric clinical trials can offer direct and indirect benefits from COVID-19 vaccination\(^11\).

**Updates on COVID-19 and vaccines**

On November 26, 2021, the WHO designated B.1.1.529 (Omicron) as a new VoC, although its pathogenicity as well as its potential to evade immune response from vaccines and natural immunity is relatively unknown\(^12\). Since other variants could emerge in the future, coordinated global responses that address vaccines and lockdown measures against SARS-CoV-2, surveillance systems that monitor viral mutations and the effectiveness of vaccines, as well
as overcoming vaccine and economic inequalities, are needed.

A third dose of the Pfizer-BioNTech vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least five months prior\(^\text{13}\). A booster of Moderna or Pfizer-BioNTech may produce antibodies against SARS-CoV-2 in organ transplant patients with an immunodepression state\(^\text{14,15}\). On August 13, 2021, the US FDA authorized a third dose of the Pfizer-BioNTech or Moderna vaccines for immunocompromised people, who are particularly at risk for severe disease\(^\text{16}\), and the EMA concluded that an extra dose of these COVID-19 vaccines may be given to these patients at least 28 days after their second dose\(^\text{17}\).

**Financial support & sponsorship:** None.

**Conflicts of Interest:** None.

### References

1. World Health Organization. *Status of COVID-19 vaccines within WHO EUL/PQ evaluation process*. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf, accessed on December 20, 2021.

2. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. *Age Ageing* 2021; 50: 279-83.

3. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. *J Pharm Sci* 2021; 110: 997-1001.

4. Dolgin E. CureVac COVID vaccine let-down spotlights mRNA design challenges. *Nature* 2021; 594: 483.

5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021; 397: 99-111.

6. GlaxoSmithKline. Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial. Available from: https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/, accessed on December 20, 2021.

7. World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issue interim policy recommendations. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1, accessed on December 20, 2021.

8. Wu ZW, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* 2021; 21: 803-12.

9. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. *Nature* 2021; 594: 161-2.

10. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. *Lancet Infect Dis* 2021; 21: e26-35.

11. Kumar VM, Pandi-Perumal SR, Trakht I, Thiagarajan SP. Strategy for COVID-19 vaccination in India: The country with the second highest population and number of cases. *NPJ Vaccines* 2021; 6: 60.

12. Ministry of Health and Family Welfare, Government of India. COVID-19 vaccine operational guidelines. Available from: https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter16.pdf, accessed on December 20, 2021.

13. Sasikala M, Shashidhar J, Deepika G, Ravikanth V, Krishna VV, Sadhana Y, et al. Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals. *Int J Infect Dis* 2021; 108: 183-6.

14. Jain J, Saurabh S, Kumar P, Verma MK, Goel AD, Gupta MK, et al. COVID-19 vaccine hesitancy among medical students in India. *Epidemiol Infect* 2021; 149: e132.

15. Thiagarajan K. What do we know about India’s Covaxin vaccine? *BMJ* 2021; 373: n997.

16. Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-bind, controlled, phase 3 trial. *Lancet* 2021; 398: 2173-84.

17. Logunov DY, Dolzhikova IV, Shchelbyakov DV, Tukhvatulin AI, Zubkova OV, Dzhurullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021; 397: 671-81.

18. World Health Organization. *The sinopharm COVID-19 vaccine: what you need to know*. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know, accessed on December 20, 2021.

19. World Health Organization. *India marks one year of COVID vaccination*. Available from: http://www.who.int/india/news/feature-stories/detail/India-marks-one-year-of-covid-vaccination, accessed on January 7, 2022.

20. Harder T, Koch J, Vugten-Bonnet S, Külper-Schiek W, Pilie A, Reda S, et al. Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: Interim results of a living systematic review, 1 January to 14 May 2021. *Euro Surveill* 2021; 26: 2100563.
21. Doroftei B, Ciobica A, Ilie OD, Maftei R, Ilea C. Discussing the reliability and efficiency of COVID-19 vaccines. Diagnostics 2021; 11: 579.

22. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci 2021; 25: 1663-9.

23. Sadarangani M, Marchant A, Kollmann TR. Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nat Rev Immunol 2021; 21: 475-84.

24. Forni G, Mantovani A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ 2021; 28: 626-39.

25. Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: Implications for vaccines. Clin Infect Dis 2020; 73: e4223-28.

26. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med 2021; 27: 205-11.

27. World Health Organization. Interim statement on booster doses for COVID-19 vaccination. Available from: www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021, accessed on January 7, 2022.

28. Liu X, Shaw RH, Stuart AV, Greenland M, Aley PK, Andrews NJ, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): A single-blind, randomised, non-inferiority trial. Lancet 2021; 398: 856-69.

29. Normark J, Vikström L, Gwon YD, Persson IL, Edin A, Björsell T, et al. Heterologous ChAdOx1 nCoV-19 and mRNA1273 vaccination. New Engl J Med 2021; 385: 1049-51.

30. Vallée A, Vasse M, Mazaux L, Bonan B, Amiel C, Zia-Chahabi S, et al. An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines. J Clin Med 2021; 10: 3817.

31. World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: guidance, 8 January 2021. Available from: http://apps.who.int/iris/handle/10665/338484, accessed on December 20, 2021.

32. World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, 25 January 2021. Available from: http://apps.who.int/iris/handle/10665/338862, accessed on December 20, 2021.

33. World Health Organization. Interim recommendations for use of the Janssen Ad26.COV2.S (COVID-19) vaccine: interim guidance, first issued 17 march 2021, updated 15 June 2021. Available from: http://apps.who.int/iris/handle/10665/341784, accessed on December 20, 2021.

34. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 vaccine AZD1222 (Vaxzevria™, SII COVISHIELD™). Available from: www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1, accessed on December 20, 2021.

35. World Health Organization. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know, 2 September 2021. Available from: http://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know, accessed on December 20, 2021.

36. World Health Organization. WHO recommendation Serum Institute of India Pvt Ltd- COVID-19 Vaccine (ChAdOxl-S [recombinant])-COVISHIELD™. Available from: http://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadoxl-s-recombinant-covishield, accessed on December 20, 2021.

37. World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG) Sinopharm. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP, accessed on September 22, 2021.

38. World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19. Available from: www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin, accessed on December 20, 2021.

39. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020; 383: 2603-15.

40. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38.

41. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: Update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 977-82.

42. Banerji A, Wickner PG, Saff R, Stone CA Jr., Robinson LB, Long AA, et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J Allergy Clin Immunol Pract 2021; 9: 1423-37.

43. Long B, Bridwell R, Gottlieb M. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines. Am J Emerg Med 2021; 49: 58-61.

44. U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048) [FDA Briefing Document]. Available from: https://www.fda.gov/media/144246/download, accessed on December 20, 2021.

45. Shimabukuro T, Nair N. Allergic Reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA 2021; 325: 780-1.

46. Shimabukuro T. Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine
47. Kounis NG, Koniaris I, de Gregorio C, Velissaris D, Petlas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines 2021; 9 : 221.

48. Erdeljic Turk V. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to allergy investigation. Clin Immunol 2021; 227 : 108748.

49. Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: Is polyethylene glycol (PEG) the culprit? Br J Anaesth 2021; 126 : e106-8.

50. Suresh P, Petchey W. ChAdOx1 nCOV-19 vaccine-induced immune thrombocytopenia and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Population based cohort study. BMJ 2021; 373 : n1114.

51. Caminati M, Guarnieri G, Senna G. Who is really at risk for anaphylaxis due to COVID-19 vaccine? Vaccines 2021; 9 : 38.

52. American College of Allergy, Asthma, & Immunology. ACAAI updates to guidance on risk of allergic reactions to COVID-19 vaccines. Available from: https://acaai.org/news/acaai-updates-guidance-risk-allergic-reactions-covid-19-vaccines, accessed on December 20, 2021.

53. Galvez R, Lund LC, Karlstad Ø, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: Single UK centre experience. BMJ Case Rep 2021; 14 : e243894.

54. Malik B, Kalantary A, Rikabi K, Kunadi A. Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson & Johnson COVID-19 vaccine. BMJ Case Rep 2021; 14 : e243975.

55. European Medicines Agency. AstraZeneca’s COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets. Available from: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood, accessed on December 20, 2021.

56. Hunter PR. Thrombosis after COVID-19 vaccination. BMJ 2021; 373 : n958.

57. Kounis NG, Koniaris I, de Gregorio C, Velissaris D, Petlas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines 2021; 9 : 221.

58. Patel SU, Khurrum R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1. BMJ Case Rep 2021; 14 : e242956.

59. Rela M, Jothimani D, Vij M, Rajakumar A, Rammohan A. Auto-immune hepatitis following COVID vaccination. J Autoimmun 2021; 123 : 102688.

60. CEPI. Consensus considerations on the assessment of the risk of disease enhancement with COVID-19 vaccines: Outcome of a coalition for epidemic preparedness from the CEPI alliance. Available from: https://taskforce.org/brighton-collaboration-cepi-covid-19-web-conference/, accessed on December 20, 2021.

61. Halstead SB, Katzelnick L. COVID-19 vaccines: Should we fear ADE? J Infect Dis 2020; 222 : 1946-50.

62. Karthik K, Senthilkumar TMA, Udhayavel S, Raj GD. Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19. Hum Vaccin Immunother 2020; 16 : 3055-60.

63. Gershwin LJ. Adverse reactions to vaccination: From anaphylaxis to autoimmunity. Vet Clin North Am Small Anim Pract 2018; 48 : 279-90.

64. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – A new era in vaccinology. Nat Rev Drug Discov 2018; 17 : 261-79.

65. Caminati M, Guarnieri G, Senna G. Who is really at risk for anaphylaxis due to COVID-19 vaccine? Vaccines 2021; 9 : 38.

66. American College of Allergy, Asthma, & Immunology. ACAAI updates to guidance on risk of allergic reactions to COVID-19 vaccines. Available from: https://acaai.org/news/acaai-updates-guidance-risk-allergic-reactions-covid-19-vaccines, accessed on December 20, 2021.

67. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – A new era in vaccinology. Nat Rev Drug Discov 2018; 17 : 261-79.

68. Rice AM, Morales AC, Ho AT, Mordstein C, Mühlhausen S, Watson S, et al. Evidence for strong mutation bias towards, and selection against, U content in SARS-CoV-2: Implications for vaccine design. Mol Biol Evol 2021; 38 : 67-83.

69. COVID-19 Genomics UK Consortium. COG-UK report on SARS-CoV-2 spike mutations of interest in the UK. Available from: https://www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2-COG-UK_SARS-CoV-2-Mutations.pdf, accessed on December 20, 2021.

70. Chakraborty C, Bhattacharya M, Sharma AR. Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity. Rev Med Virol 2021; 32 : e2270.

71. GISAID. Genomic epidemiology of novel coronavirus- Global subsampling. Available from: https://nextstrain.org/ncov/gisaid/global, accessed on December 20, 2021.

72. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: Real-time tracking of pathogen evolution. Bioinformatics 2018; 34 : 4121-3.

73. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021; 596 : 276-80.
Neutralising capacity against Delta
Efficacy of ChAdOx1 nCoV-19 (AZD1222) Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/, accessed on December 20, 2021.

Centers for Disease Control and Prevention. New variants of the virus that causes COVID-19. Available from: https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html, accessed on December 20, 2021.

Yadav PD, Sapkal GN, Ella R, Sahay RR, Nyayanit DA, Patil DY, et al. Neutralization of beta and delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. J Travel Med 2021; 28 : taab104.

Lazarevic I, Pravica V, Miljanovic D, Cupic M. Immune evasion of SARS-CoV-2 emerging variants: What have we learnt so far? Viruses 2021; 13 : 1192.

Sharun K, Tiwari R, Dhama K, Emran TB, Rabaan AA, Al Muta’ar A. Emerging SARS-CoV-2 variants: Impact on vaccine efficacy and neutralizing antibodies. Hum Vaccin Immunother 2021; 17 : 3491-4.

Emary KRW, Golubchik T, Aley PK, Mestanza O, Galarza M, Bibi S, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202102/01 (B.1.1.7): An exploratory analysis of a randomised controlled trial. Lancet 2021; 397 : 1351-62.

University of Oxford. ChAdOx1 nCoV-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young south African adults. Available from: https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection, accessed on December 20, 2021.

Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial. Available from: https://ir.novavax.com/2021-01-28-Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial, accessed on December 20, 2021.

Mahase E. COVID-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ 2021; 372 : n296.

Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants – Clinical, public health, and vaccine implications. N Engl J Med 2021; 384 : 1866-8.

Johnson & Johnson. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of Its Phase 3 ENSEMBLE Trial; 2021. Available from: https://www.janssen.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints, accessed on December 20, 2021.

Moderna. Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the republic of South Africa. Available from: https://investors.modernatx.com/news/news-details/2021/Moderna-COVID-19-Vaccine-Retains-Neutralizing-Activity Against-Emerging- Variants-First-Identified-in-the-U-K--and-the-Republic-of-South-Africa-01-25-2021/default.aspx, accessed on December 20, 2021.

Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgaugudi P, Oosthuysen B, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021; 27 : 622-5.

Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 384 : 1885-98.

Xie X, Liu Y, Liu J, Zhang X, Zou J, Fontes-Garfias CR, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med 2021; 27 : 620-1.

Betti M, Bragazzi N, Hefferman J, Kong J, Raad A. Could a new COVID-19 mutant strain undermine vaccination efforts? A mathematical modelling approach for estimating the spread of B.1.1.7 using Ontario, Canada, as a case study. Vaccines 2021; 9 : 592.

Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021; 397 : 2461-2.

Abu-Raddad LJ, Chemaitelly H, Butt AA; National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 385 : 187-9.

Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70 : 1059-62.

Lustig Y, Zuckerman N, Itzkan I, Atari N, Kliker L, Regev-Yochay G, et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in healthcare workers, Israel. Euro Surveill 2021; 26 : 2100557.

Aleem A, Akbar Samad AB, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). 2022 Feb 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls publishing; 2022 Jan–.
99. Yadav PD, Sahay RR, Sapkal G, Nyayanit D, Shete AM, Deshpande G, et al. Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152. J Travel Med 2021; 28 : taab154.

100. Ujjainiya R, Tyagi A, Sardana V, Naushin S, Bhatheja N, Kumar K, et al. High failure rate of ChAdOx1 in healthcare workers during Delta variant surge: A case for continued use of masks post-vaccination. medRxiv 2021; doi: 10.1101/2021.02.28.21252621.

101. Nature. The COVID vaccine challenges that lie ahead. Available from: https://media.nature.com/original/magazine-assets/d41586-020-03334-w/d41586-020-03334-w.pdf, accessed on December 20, 2021.

102. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020; 2 : 1069-76.

103. Andrew MK, Shinde V, Ye L, Hatchette T, Haguinet F, Dos Santos G, et al. The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J Infect Dis 2017; 216 : 405-14.

104. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021; 396 : 1979-93.

105. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet 2021; 397 : 881-91.

106. Bardaji A, Sevene E, Cutland C, Menéndez C, Omer SB, Aguado T, et al. The need for a global COVID-19 maternal immunisation research plan. Lancet 2021; 397 : e17-8.

107. Wastnedge EA, Reynolds RM, van Boeckel SR, Stock SJ, Denison FC, Maybin JA, et al. Pregnancy and COVID-19. Physiol Rev 2021; 101 : 303-18.

108. Oakes MC, Kernberg AS, Carter EB, Foeller ME, Palanisamy A, Raghiraman N, et al. Pregnancy as a risk factor for severe coronavirus 2019 (COVID-19) disease using standardized clinical criteria. Am J Obstet Gynecol 2021; 3 : 100319.

109. Stafford IA, Parchem JG, Sibai BM. The COVID-19 vaccine in pregnancy: Risks, benefits and recommendations. Am J Obstet Gynecol 2021; 224 : P484-95.

110. Rasmussen SA, Kelley CF, Horton JP, Jamieson DJ. Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: What obstetricians need to know. Obstet Gynecol 2021; 137 : 408-14.

111. Kao CM, Orenstein WA, Anderson EJ. The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children. Clin Infect Dis 2021; 72 : 515-8.

112. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021; 600 : 21.

113. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: An observational study. Lancet 2021; 398 : 2093-100.

114. Kamar N, Abravanel F, Marion O, Couat C, Izojet J, Del Bello A. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med 2021; 385 : 661-2.

115. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med 2021; 385 : 1244-6.

116. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised, accessed on December 20, 2021.

117. European Medicines Agency. Comirnaty and Spikevax: EMA recommendations on extra doses and booster. Available from: https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters, accessed on December 20, 2021.